Advanced therapies, including cell and gene therapies, are transforming the treatment landscape, offering new possibilities for patients with serious and life-threatening diseases. However, delivering these therapies requires more than advanced science and manufacturing. Successful patient treatment demands a carefully coordinated supply chain that integrates logistics, quality assurance, regulatory compliance and clinical operations.
Unlike conventional medicines, many advanced therapies have specific handling requirements, limited shelf lives or patient-specific manufacturing processes. These characteristics mean that traditional pharmaceutical supply-chain models may not always be appropriate.
The supply chain must therefore be designed around the patient and the treatment pathway from the outset, rather than treated as a downstream logistics consideration.
The Patient is at the Centre of the Supply Chain
It is essential that the patient remains the central priority when designing and establishing a supply chain for an advanced therapy. For example, with autologous cell therapies, the process often begins with collecting cells from the patient, transporting them to a manufacturing facility and returning the finished therapy to the treatment centre for administration to that same patient.
This involves multiple stakeholders, including collection centres, logistics providers, manufacturers, testing laboratories, Qualified Persons (QPs) responsible for batch certification, and clinical sites.
Each stakeholder has a critical role, and delays at any stage can affect the treatment schedule. Collection appointments, manufacturing capacity, transport arrangements, testing, product release and clinical site availability must therefore be coordinated well in advance. An experienced and responsive team is essential to achieving effective coordination.
Protecting Product Quality Throughout the Journey
Many advanced therapies are sensitive to temperature, humidity, transit duration and handling conditions. Depending on the product, maintaining product quality may require stringent ultra-low-temperature storage and monitoring, including the use of liquid nitrogen.
These requirements must be considered and incorporated into the supply-chain strategy, supported by appropriate procedures, qualified equipment and documented controls.
Key considerations include:
- Temperature control: Maintaining appropriate storage and transport conditions, with suitable monitoring and temperature excursion management.
- Transport qualification: Ensuring that shipping systems and distribution arrangements are suitable for the product.
- Contingency planning: Establishing responses to delays, equipment failures and temperature excursions.
- Receiving arrangements: Confirming that the destination facility can receive and store the product under the required conditions.
The appropriate controls will depend on the specific requirements of the advanced therapy. A risk-based approach is essential to maintaining product quality throughout the supply chain.
Maintaining Chain of Identity and Chain of Custody
For patient-specific therapies, ensuring that the right product reaches the right patient is fundamental.
Chain of identity (COI) maintains the link between the patient, their collected starting material and the resulting medicinal product. Chain of custody (COC) documents the possession and handling of materials and products throughout their journey.
These controls must extend across collection centres, couriers, manufacturers, testing laboratories and treatment facilities. Consistent identification, verification procedures and documentation at every handover help minimise the risk of errors.
Where multiple organisations and electronic systems are involved, differences in identifiers and processes can introduce additional complexity. These interfaces should be addressed during supply-chain design, with patient confidentiality also considered in labelling and information-sharing arrangements. Traceability is not simply a documentation exercise but it is a fundamental patient-safety control.
Integrating Qualified Person (QP) Certification into the Treatment Timeline
Quality control testing, thorough review of manufacturing documentation (including batch records) and Qualified Person (QP) certification are essential steps in ensuring regulatory compliance and product quality in the EU and UK.
For advanced therapies, these activities may need to be coordinated within a defined treatment window. The applicable requirements will depend on the product, regulatory framework and relevant clinical trial or marketing authorisation arrangements.
Early planning should establish the responsibilities of the manufacturer and QP, applicable importation requirements, documentation flows and procedures for escalating quality issues. Delays in testing or documentation can affect not only product release but also transport arrangements, receipt of shipments at clinical sites and patient treatment schedules.
QP certification should therefore be embedded within the overall supply-chain strategy from the outset, rather than treated as a standalone final step. For advanced therapies, early engagement with an experienced QP service provider is particularly important to ensure that regulatory requirements are addressed proactively and the supply chain is designed to meet the specific needs of both the product and the patient.
Building Resilience Through Early Planning
Even well-designed supply chains can encounter unexpected challenges, including flight delays, extended customs holds, manufacturing process changes or issues at receiving sites. For therapies with limited stability or patient-specific manufacturing windows, these disruptions can have significant consequences.
Sponsors should establish clear escalation procedures, identify alternative transport arrangements where appropriate, confirm suitable storage options and ensure that regulatory documentation is prepared before shipment. Responsibilities for managing delays, deviations and other disruptions should also be agreed in advance.
As clinical trials expand into additional countries, the supply chain may need to evolve. A supply-chain model that is suitable for a small, early-phase study may not be fit for purpose as the programme scales to a larger, multi-centre clinical trial.
By addressing these considerations early, clearly defining responsibilities and establishing robust processes across participating organisations, sponsors can build more resilient and predictable supply chains.
At HiTech Health, we recognise the importance of integrating quality, regulatory and supply-chain considerations to support the delivery of advanced therapies. Early collaboration can help sponsors navigate operational complexity while keeping the focus on delivering the right therapy to the right patient.
If you are developing an advanced therapy and planning clinical supply in the EU or UK, engaging an experienced QP and Quality team early can help identify potential challenges before they affect your programme. Contact our team today and schedule a call to learn more about our services for the EU and UK markets.